Drug firm Roche Pharma India on Thursday said it has expanded its partnership with domestic pharma major Cipla to further improve access to its key oncology medicines in India.
Roche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India," the company said in a statement.
The two companies had previously entered into a similar agreement in February 2018 for promotion and distribution of tocilizumab (Actemra) and other products, it added.
"We have been working as a